CYBERDYNE : Financial result briefing for the consolidated three months ended June 30, 2023

Consolidated Financial Result Briefing for the three months ended June 30, 2023

CYBERDYNE, Inc. August 14, 2023

Consolidated fnancial results (IFRS)

Year-on-year comparison for the fscal year ended March 31, 2023

(Unit: Millions of yen)

	FY2022	FY2023	+/-	+/-%
	Q1	Q1
Revenue	751	1,045	+294 *1	+39.1％
(Gross profit)	☆ (457)	(566)	(+108)	(+23.7%)
			*２
Operating profit	-178	-308	-130	ー
		*３ *４
Profit before tax	372	767	+395	+106.2%
		*５
Profit attributable to	241	330	+89	+36.9%
owner of the parent
EBITDA	-88	-215	-127	ー

*EBITDA = Operating income + Depreciation and amortization ± Other income and expenses

*1 Increase in revenue（294M）（YoY）

Treatment Service +110M (Increase of sale from RISE Group in the USA) Expansion of new business +162M (Acquisition of

German Mobility company)

*２Increase in SG&A (254M) (YoY)

SG&A expenses of two foreign consolidated subsidiary acquired through M&A +230M

*３ Investment securities 868M (Net) *443M in FY2022 Q1

Finance income (gain on valuation) 246M Gains related to CEJ 623M

*４ Other Exchange loss -113M (+19M YoY)

*5 Income tax 482M (YoY)

Tax effect on valuation gains 392M

• Transferred a portion of other SG&A expenses in FY2022 Q1 to cost of sales due to a review of the cost of sales for treatment services

3

Business performance by type of business : Revenue/ Gross proft (margin)

(Unit: Millions of yen)

		FY2022	FY2023	+/-	+/-%
		Q1	Q1
Rental of product	Profit	388	411	+22	+6%
☆ Revenue	170	196	+26	+15%
	(Margin)	(44%)	(48%)
Treatment service	Profit	286	396	+110	+38%
☆ Revenue	-3	-131	-129	-
	(Margin)	(-1%)	(-33%)
New business	Profit	77	239	+162	+210%
☆ Revenue	-30	-85	-55	-
	(Margin)	(-39%)	(-36%)
☆☆	Adjusted
R&D and head office	-316	-288	+28
expenses	Amount
Total	Profit	751	1,045	+294	+39%
Revenue	-178	-308	-130	-
	(Margin)	(-24%)	(-30%)

• Operating income by business segment is the amount of profit/loss after deducting operating expenses from revenue by business segment.
• RD expenses, head office expenses, etc. are adjustments of R&D expenses, head office administrative expenses, other income and expenses, etc.

• Product rental: Rental income of the Group's products (including some sales)
• Treatment services: Income from treatment fees at the Group's treatment facilities (including some service fees at Robocare Centers)
• Development of new business areas: Revenue from sales in the Group's new business areas (Mobility subsidiary, Sleep Apps subsidiary, etc.)

4

Rental revenue by each products

Rental income Medical Lower Limb Type (overseas) +48M (+61%)

(Unit: Millions of yen)

	Product classification	Japan	Outside Japan	Total
	HAL Lower Limb Type	83 +1%	127 +61%	209 +30%
	(Medical)	(82)	(79)	(161)
For Hospitals	HAL Lower Limb Type	37	-	37
(improving function)	(Non-medical)	(45)	23	(45)
	HAL Single Joint Type	22	45
	(27)	(21)	(47)
Well-being	HAL Lumbar Type	25	28	53
(38)	(26)	(64)
	HAL Lumbar Type	11	-	11
Labor Support	(18)	(18)
Mobile Robot (CL02 etc)	21	-	21
	(18)	(18)
		19
Medical Application	Photo-acoustic Imaging	0	19
Research	(Acoustic X)	(0)	(17)	(17)
	Other	8	6	14
	(11)	(7)	(18)
	Total	208 -13%	203 +35%	411 +6%
	(239)	(150)	(388)

Number on the top row：FY2023 Q1

(Number in the brackets in the bottom row) : FY2022 Q1

5